EdgarLookup

CPS TECHNOLOGIES CORP/DE/ — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that CPS TECHNOLOGIES CORP/DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
2.9%
Profit Margin
Net income ÷ revenue
1.4%
Return on Assets
Net income ÷ assets
0.2x
Debt-to-Equity
Total liabilities ÷ equity
-5%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2017 Dec 30, 2017 $14.58M Mar 12, 2018
FY2017 Dec 31, 2016 $15.35M Mar 12, 2018
FY2017 Dec 26, 2015 $21.76M Mar 12, 2018
FY2016 Dec 27, 2014 $23.14M Mar 8, 2017
FY2015 Dec 28, 2013 $21.41M Mar 9, 2016
FY2014 Dec 29, 2012 $14.05M Mar 24, 2015
FY2013 Dec 31, 2011 $19.81M Mar 17, 2014
FY2012 Dec 25, 2010 $21.40M Mar 27, 2013
FY2011 Dec 26, 2009 $12.98M Mar 30, 2012

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $32.60M Mar 3, 2026
FY2025 Dec 28, 2024 $21.12M Mar 3, 2026
FY2024 Dec 30, 2023 $27.55M Mar 17, 2025
FY2023 Dec 31, 2022 $26.59M Aug 2, 2024
FY2022 Dec 25, 2021 $22.45M Mar 16, 2023
FY2021 Dec 26, 2020 $20.87M Mar 10, 2022
FY2020 Dec 28, 2019 $21.47M Mar 17, 2021
FY2019 Dec 29, 2018 $21.58M Mar 13, 2020
FY2018 Dec 30, 2017 $14.58M Mar 15, 2019

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $5.29M Mar 3, 2026
FY2025 Dec 28, 2024 ($118.6K) Mar 3, 2026
FY2024 Dec 30, 2023 $6.83M Mar 17, 2025
FY2023 Dec 31, 2022 $7.30M Aug 2, 2024
FY2022 Dec 25, 2021 $4.79M Mar 16, 2023
FY2021 Dec 26, 2020 $4.17M Mar 10, 2022
FY2020 Dec 28, 2019 $2.54M Mar 17, 2021
FY2019 Dec 29, 2018 $2.91M Mar 13, 2020
FY2018 Dec 30, 2017 $1.66M Mar 15, 2019
FY2017 Dec 31, 2016 $2.16M Mar 12, 2018

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $420.4K Mar 3, 2026
FY2025 Dec 28, 2024 ($3.14M) Mar 3, 2026
FY2024 Dec 30, 2023 $1.37M Mar 17, 2025
FY2023 Dec 31, 2022 $2.13M Aug 2, 2024
FY2022 Dec 25, 2021 $3.22M Mar 16, 2023
FY2021 Dec 26, 2020 $908.1K Mar 10, 2022
FY2020 Dec 28, 2019 ($638.2K) Mar 17, 2021
FY2019 Dec 29, 2018 ($3.71M) Mar 13, 2020
FY2019 Dec 30, 2017 ($1.72M) Mar 13, 2020
FY2017 Dec 31, 2016 ($453.6K) Mar 12, 2018

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $444.0K Mar 3, 2026
FY2025 Dec 28, 2024 ($4.38M) Mar 3, 2026
FY2024 Dec 30, 2023 $1.70M Mar 17, 2025
FY2023 Dec 31, 2022 $2.23M Aug 2, 2024
FY2022 Dec 25, 2021 $513.0K Mar 16, 2023
FY2021 Dec 26, 2020 $914.2K Mar 10, 2022
FY2020 Dec 28, 2019 ($597.2K) Mar 17, 2021
FY2019 Dec 29, 2018 ($900.6K) Mar 13, 2020
FY2018 Dec 30, 2017 ($1.95M) Mar 15, 2019
FY2017 Dec 31, 2016 ($1.18M) Mar 12, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $867.7K Mar 3, 2026

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $4.85M Mar 3, 2026
FY2025 Dec 28, 2024 $4.26M Mar 3, 2026
FY2024 Dec 30, 2023 $5.13M Mar 17, 2025
FY2023 Dec 31, 2022 $5.07M Aug 2, 2024
FY2022 Dec 25, 2021 $4.28M Mar 16, 2023
FY2021 Dec 26, 2020 $3.26M Mar 10, 2022
FY2020 Dec 28, 2019 $3.14M Mar 17, 2021
FY2019 Dec 29, 2018 $3.81M Mar 13, 2020
FY2018 Dec 30, 2017 $3.61M Mar 15, 2019
FY2017 Dec 31, 2016 $3.34M Mar 12, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $243.6K Mar 3, 2026
FY2025 Dec 28, 2024 ($3.48M) Mar 3, 2026
FY2024 Dec 30, 2023 $1.27M Mar 17, 2025
FY2023 Dec 31, 2022 $3.55M Aug 2, 2024
FY2022 Dec 25, 2021 $2.01M Mar 16, 2023
FY2021 Dec 26, 2020 $1.67M Mar 10, 2022
FY2020 Dec 28, 2019 ($1.26M) Mar 17, 2021
FY2019 Dec 29, 2018 ($373.6K) Mar 13, 2020
FY2018 Dec 30, 2017 ($1.79M) Mar 15, 2019
FY2017 Dec 31, 2016 $596.3K Mar 12, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $730.7K Mar 3, 2026
FY2025 Dec 28, 2024 $994.3K Mar 3, 2026
FY2024 Dec 30, 2023 $718.3K Mar 17, 2025
FY2023 Dec 31, 2022 $439.8K Aug 2, 2024
FY2022 Dec 25, 2021 $514.3K Mar 16, 2023
FY2021 Dec 26, 2020 $323.0K Mar 10, 2022

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $29.51M Mar 3, 2026
FY2025 Dec 28, 2024 $18.88M Mar 3, 2026
FY2024 Dec 30, 2023 $21.60M Mar 17, 2025
FY2023 Dec 31, 2022 $21.68M Aug 2, 2024
FY2022 Dec 25, 2021 $18.80M Mar 16, 2023
FY2021 Dec 26, 2020 $8.32M Mar 10, 2022

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $4.88M Mar 3, 2026
FY2025 Dec 28, 2024 $4.36M Mar 3, 2026
FY2023 Dec 31, 2023 $4.28M Mar 14, 2024
FY2024 Dec 30, 2023 $4.28M Mar 17, 2025
FY2023 Dec 31, 2022 $5.97M Aug 2, 2024
FY2022 Dec 25, 2021 $5.63M Mar 16, 2023
FY2021 Dec 26, 2020 $1.96M Mar 10, 2022
FY2020 Dec 28, 2019 $3.69M Mar 17, 2021
FY2019 Dec 29, 2018 $2.66M Mar 13, 2020
FY2013 Dec 28, 2013 $2.28M Mar 17, 2014

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $24.64M Mar 3, 2026
FY2025 Dec 28, 2024 $14.51M Mar 3, 2026
FY2023 Dec 31, 2023 $17.32M Mar 14, 2024
FY2025 Dec 30, 2023 $17.32M Mar 3, 2026
FY2023 Dec 31, 2022 $15.71M Aug 2, 2024
FY2023 Dec 25, 2021 $13.17M Aug 2, 2024
FY2022 Dec 26, 2020 $6.36M Mar 16, 2023
FY2021 Dec 28, 2019 $5.33M Mar 10, 2022
FY2019 Dec 29, 2018 $5.84M Mar 13, 2020
FY2018 Dec 30, 2017 $9.32M Mar 15, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 ($25.47M) Mar 3, 2026
FY2025 Dec 28, 2024 ($25.89M) Mar 3, 2026
FY2023 Dec 31, 2023 ($22.75M) Mar 14, 2024
FY2024 Dec 30, 2023 ($22.75M) Mar 17, 2025
FY2023 Dec 31, 2022 ($24.13M) Aug 2, 2024
FY2022 Dec 25, 2021 ($26.26M) Mar 16, 2023
FY2021 Dec 26, 2020 ($29.47M) Mar 10, 2022
FY2020 Dec 28, 2019 ($30.38M) Mar 17, 2021
FY2019 Dec 29, 2018 ($29.74M) Mar 13, 2020
FY2018 Dec 30, 2017 ($26.04M) Mar 15, 2019

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $4.47M Mar 3, 2026
FY2025 Dec 28, 2024 $3.28M Mar 3, 2026
FY2024 Dec 30, 2023 $8.81M Mar 17, 2025
FY2023 Dec 31, 2022 $8.27M Aug 2, 2024
FY2022 Dec 25, 2021 $5.05M Mar 16, 2023
FY2021 Dec 26, 2020 $195.2K Mar 10, 2022
FY2020 Dec 28, 2019 $134.0K Mar 17, 2021
FY2020 Dec 29, 2018 $628.8K Mar 17, 2021
FY2019 Dec 30, 2017 $1.34M Mar 13, 2020
FY2018 Dec 31, 2016 $3.41M Mar 15, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2024 Dec 28, 2024 $8.1K Mar 17, 2025
FY2023 Dec 30, 2023 $54.9K Aug 2, 2024
FY2022 Dec 31, 2022 $98.7K Mar 16, 2023
FY2021 Dec 31, 2021 $154.6K Mar 10, 2022

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 0 Mar 3, 2026
FY2025 Dec 28, 2024 0 Mar 3, 2026
FY2024 Dec 30, 2023 0 Mar 17, 2025
FY2023 Dec 31, 2022 0 Aug 2, 2024
FY2022 Dec 25, 2021 0 Mar 16, 2023
FY2021 Dec 26, 2020 0 Mar 10, 2022
FY2020 Dec 28, 2019 0 Mar 17, 2021
FY2019 Dec 29, 2018 0 Mar 13, 2020
FY2018 Dec 30, 2017 0 Mar 15, 2019
FY2017 Dec 31, 2016 0 Mar 12, 2018

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 0 Mar 3, 2026
FY2025 Dec 28, 2024 0 Mar 3, 2026
FY2024 Dec 30, 2023 0 Mar 17, 2025
FY2023 Dec 31, 2022 0 Aug 2, 2024
FY2022 Dec 25, 2021 0 Mar 16, 2023
FY2021 Dec 26, 2020 0 Mar 10, 2022
FY2020 Dec 28, 2019 0 Mar 17, 2021
FY2019 Dec 29, 2018 0 Mar 13, 2020
FY2018 Dec 30, 2017 0 Mar 15, 2019
FY2017 Dec 31, 2016 0 Mar 12, 2018

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 17.99M Mar 3, 2026
FY2025 Dec 28, 2024 14.53M Mar 3, 2026
FY2023 Dec 31, 2023 14.52M Mar 14, 2024
FY2024 Dec 30, 2023 14.52M Mar 17, 2025
FY2023 Dec 31, 2022 14.45M Aug 2, 2024
FY2022 Dec 25, 2021 14.35M Mar 16, 2023
FY2021 Dec 26, 2020 13.31M Mar 10, 2022
FY2020 Dec 28, 2019 13.21M Mar 17, 2021
FY2019 Dec 29, 2018 13.21M Mar 13, 2020
FY2018 Dec 30, 2017 13.20M Mar 15, 2019